B

Belite Bio
D

BLTE

171.330
USD
-1.30
(-0.75%)
مغلق
حجم التداول
3,892
الربح لكل سهم
-0
العائد الربحي
-
P/E
-74
حجم السوق
6,847,257,248
المقالات
المزيد

العنوان: Belite Bio

القطاع: Healthcare
الصناعة: Biotechnology
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includesa small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.